Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the most profitable biotech stocks to buy. H.C. Wainwright ...
Pfizer is racing towards patent cliffs that will lead to even worse financial results. Vertex Pharmaceuticals is posting ...
To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy ...
Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.
For two decades, US biotech Vertex (Nasdaq: VRTX) built a reputation as one of the few companies to pair cutting-edge science ...
Advocacy groups form a buyer’s club to obtain generic versions of pricey Vertex cystic fibrosis drug
Frustrated by the price of a lifesaving cystic fibrosis treatment sold by Vertex Pharmaceuticals, a group of families is ...
Vertex, Inc. (NASDAQ: VERX) announced CEO David DeStefano's retirement and succession plan. Christopher Young chosen as new ...
Jupiter Endovascular, which was formed by Neptune Medical a little more than a year ago, shared positive results from the ...
The new features are designed for companies training massive AI models, making it easier to manage complex workloads and keep ...
A former executive at Microsoft, McAfee and Cisco becomes the fourth CEO in Vertex's 47-year history.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback